Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Monolithic Power Systems Inc (MPWR) vs TransMedics Group Inc (TMDX) Price & Performance

Monolithic Power Systems IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Monolithic Power Systems Inc vs TransMedics Group Inc — how do they compare? Monolithic Power Systems Inc trades at $1,385.25 (market cap $65.28B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Monolithic Power Systems Inc is far larger — about 25.7× TransMedics Group Inc's market cap, and Monolithic Power Systems Inc pays a 0.6% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

MPWRTMDX
Market Cap
$65.28B$2.54B
Sector
UtilitiesTechnology
52-Week High
$1.69K$150.42
52-Week Low
$711.24$61.99
Enterprise Value
$63.94B$2.94B
Dividend Yield
0.6%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Monolithic Power Systems Inc

Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.

Read more on MPWR

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX